Results 1 to 10 of about 614,006 (307)

How CAR T Cells Breathe

Cells, 2022
The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism.
Christopher Forcados, Sandy Joaquina, Nicholas Paul Casey, Benjamin Caulier, Sébastien Wälchli   +4 more
doaj   +4 more sources

CAR‐Aptamers Enable Traceless Enrichment and Monitoring of CAR‐Positive Cells and Overcome Tumor Immune Escape

Advanced Science
Chimeric antigen receptor (CAR)‐positive cell therapy, specifically with anti‐CD19 CAR‐T (CAR19‐T) cells, achieves a high complete response during tumor treatment for hematological malignancies. Large‐scale production and application of CAR‐T therapy can
Hang Zhou, Tuersunayi Abudureheman, Wei‐Wei Zheng, Li‐Ting Yang, Jian‐Min Zhu, Ai‐Bin Liang, Cai‐Wen Duan, Kaiming Chen   +7 more
doaj   +2 more sources

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function

Frontiers in Immunology, 2022
The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and exhaustion markers, affects the long-term functionality of CAR-T cells.
Masaya Suematsu, Shigeki Yagyu, Nobuyoshi Nagao, Susumu Kubota, Yuto Shimizu, Miyuki Tanaka, Yozo Nakazawa, Toshihiko Imamura   +7 more
doaj   +1 more source

Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway

Oncogenesis, 2021
Pancreatic carcinoma (PC) is one of the most common malignancies. Chimeric antigen receptor (CAR)-modified T cells has achieved remarkable efficacy in the treatment of hematological malignancies.
Yaoxin Gao, Haizhen Lin, Dandan Guo, Sijia Cheng, Ying Zhou, Li Zhang, Jie Yao, Muhammad Asad Farooq, Iqra Ajmal, Yixin Duan, Cong He, Lei Tao, Shijia Wu, Mingyao Liu, Wenzheng Jiang   +14 more
doaj   +1 more source

Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological cancers and is currently being investigated for solid tumours, including high-grade glioma brain tumours.
Abler, Daniel, Adhikarla, Vikram, Barish, Michael, Branciamore, Sergio, Brown, Christine E, Cho, Heyrim, Frankhouser, David, Gutova, Margarita, Machuca, Vanessa, Maestrini, Davide, Rockne, Russell C, Sahoo, Prativa, Wang, Dongrui, Yang, Xin   +13 more
core   +2 more sources

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

Advanced Science, 2023
The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide
Chan Liao, Yajie Wang, Yanjie Huang, Yanting Duan, Yan Liang, Jiangqing Chen, Jie Jiang, Kai Shang, Chun Zhou, Ying Gu, Nan Liu, Xun Zeng, Xiaofei Gao, Yongmin Tang, Jie Sun   +14 more
doaj   +1 more source

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional programs that regulate the fate of CAR-T cells after infusion remain poorly ...
Adair, Jennifer E., DeBerg, Hannah A., Enstrom, Mark R., Gersuk, Vivian, Gottardo, Raphaël, Hanafi, Laïla-Aïcha, Hawkins, Reed, Kiem, Hans-Peter, Linsley, Peter S., Maloney, David G., Pande, Dnyanada, Riddell, Stanley R., Sheih, Alyssa, Turtle, Cameron J., Voillet, Valentin, Wohlfahrt, Martin E., Yajima, Masanao   +16 more
core   +1 more source

TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss

Cancer Cell International, 2021
Background To investigate the effect of TriBAFF-CAR-T cells on hematological tumor cells. Methods TriBAFF-CAR-T and CD19-CAR-T cells were co-cultured with BAFFR-bearing B-cell malignancies at different effector/target ratios to evaluate the anti-tumor ...
Guangchao Li, Qing Zhang, Zhi Liu, Huijuan Shen, Yangmin Zhu, Zhao Zhou, Wen Ding, Siqi Han, Jie Zhou, Ruiming Ou, Min Luo, Shuang Liu   +11 more
doaj   +1 more source

Impact of Manufacturing Procedures on CAR T Cell Functionality

Frontiers in Immunology, 2022
The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in the past few decades. As of today, there are six CAR T cell products that have been approved by the FDA: KYMRIAH (tisagenlecleucel, CD19 CAR T cells), YESCARTA ...
Norihiro Watanabe, Feiyan Mo, Feiyan Mo, Mary Kathryn McKenna   +3 more
doaj   +1 more source

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. [PDF]

, 2014
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages.
Albelda, Steven M., Antzis, Michael, Cotner, Cody E., Durham, Amy C., Johnson, Laura A., June, Carl H., Kapoor, Veena, Lo, Albert, Majumdar, Rajrupa S., Puré, Ellen, Scholler, John, Solomides, MD, Charalambos C., Sun, Jing, Wang, Liang-Chuan S.   +13 more
core   +2 more sources